The American Society of Clinical Psychopharmacology (ASCP) task force on the deprescribing of psychotropic medications for mood disorders: Delphi expert consensus
The British Journal of Psychiatry · 2026-11 · 229 (5) · 550-558
DOI: 10.1192/bjp.2026.10580 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The British Journal of Psychiatry, online erschienen am 25.03.2026. Verfasst von Joseph F Goldberg und 41 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Deprescriptions, Psychotropic Drugs, Major Depressive Disorder, Bipolar Disorder. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
The American Society of Clinical Psychopharmacology convened a 45-member international expert task force to identify circumstances supporting the deprescribing of core psychotropic medications for major depressive disorder (MDD) and bipolar disorders. Three Delphi survey rounds plus a selective literature review identified points of consensus (predefined as ≥75% agreement) about when antidepressant, antipsychotic, mood stabiliser and sedative-hypnotic deprescribing is warranted. Twenty out of 32 statements (63%) achieved consensus across seven thematic areas. In MDD, panellists favoured discontinuing antidepressants when mechanisms of action are duplicative, adequate trials produce ≤25% improvement or loss of prior efficacy cannot be regained through dose increases or augmentations. Indefinite antidepressant maintenance in MDD was favoured after three or more lifetime episodes. In bipolar disorder, antidepressant deprescribing was favoured in the setting of rapid cycling, mixed features or emerging mania/hypomania symptoms; and discouraged if prior antidepressant cessation led to relapse. In nonpsychotic mood disorders, panellists favoured deprescribing antipsychotics that caused significant weight gain or tardive dyskinesia over adding pharmacological antidotes. Deprescribing to achieve an eventual medication-free status was considered inappropriate, in bipolar type 1, but not necessarily bipolar type 2 disorder. Although individualised circumstances necessarily inform psychopharmacology management, clinical presentations that misalign with existing pharmacotherapies may signal the desirability of cautious deprescribing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
- Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
- Department of Psychiatry, SUNY Upstate Medical University, Syracuse, New York, USA.
- Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Academic Department of Psychiatry, Kolling Institute, Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
ORCID-Profile: Joseph F Goldberg, Roger S McIntyre, Gin S Malhi, Manish K Jha, Michael Berk, Siegfried Kasper, Martha Sajatovic, Michael J Ostacher, Roy H Perlis, Toshi A Furukawa, Eduard Vieta, Allan H Young, Scott T Aaronson, Jose M Rubio-Lorente
Zitieren
APA
Goldberg, J. F., Swartz, H. A., McIntyre, R. S., Mago, R., Malhi, G. S., Jha, M. K., Berk, M., Kasper, S., Freeman, M. P., Gitlin, M. J., Sajatovic, M., Ostacher, M. J., Citrome, L., Iosifescu, D. V., Perlis, R. H., Furukawa, T. A., Vieta, E., Thase, M. E., Young, A. H., …, & Clayton, A. H. (2026). The American Society of Clinical Psychopharmacology (ASCP) task force on the deprescribing of psychotropic medications for mood disorders: Delphi expert consensus. The British Journal of Psychiatry, 229(5), 550-558. https://doi.org/10.1192/bjp.2026.10580
Vancouver
Goldberg JF, Swartz HA, McIntyre RS, Mago R, Malhi GS, Jha MK, et al. The American Society of Clinical Psychopharmacology (ASCP) task force on the deprescribing of psychotropic medications for mood disorders: Delphi expert consensus. The British Journal of Psychiatry. 2026;229(5):550-558. doi:10.1192/bjp.2026.10580
BibTeX
@article{Goldberg2026,
author = {Goldberg, Joseph F and Swartz, Holly A and McIntyre, Roger S and Mago, Rajnish and Malhi, Gin S and Jha, Manish K and Berk, Michael and Kasper, Siegfried and Freeman, Marlene P and Gitlin, Michael J and Sajatovic, Martha and Ostacher, Michael J and Citrome, Leslie and Iosifescu, Dan V and Perlis, Roy H and Furukawa, Toshi A and Vieta, Eduard and Thase, Michael E and Young, Allan H and Tohen, Mauricio and Nierenberg, Andrew A and Macaluso, Matt and Shelton, Richard C and Correll, Christoph U and Aaronson, Scott T and Rosenblat, Joshua D and Gorwood, Philip and Khan, Arifulla and Kupka, Ralph and Cohen, Lawrence J and Mitchell, Philip B and Frye, Mark A and Sanacora, Gerard and Kane, John M and Rubio-Lorente, Jose M and Goodman, David W and Zohar, Joseph and Davis, Lori and Gupta, Swapnil and Steingard, Sandra and Zarate, Carlos A and Clayton, Anita H},
title = {The American Society of Clinical Psychopharmacology (ASCP) task force on the deprescribing of psychotropic medications for mood disorders: Delphi expert consensus},
journal = {The British Journal of Psychiatry},
year = {2026},
volume = {229},
number = {5},
pages = {550--558},
doi = {10.1192/bjp.2026.10580}
}
EUVIMED